SOPHiA GENETICS and Complete Genomics Integrate Sequencing and AI Analytics to Accelerate Adoption of Precision Medicine
SOPHiA GENETICS (NASDAQ: SOPH) and Complete Genomics announced a collaboration on November 11, 2025 to co-market MSK-ACCESS® and MSK-IMPACT® powered with SOPHiA DDM™ on Complete Genomics' new DNBSEQ-T1+ sequencing platform.
The integrated sample-to-report workflow targets precision oncology research by combining MSK-validated assays and AI analytics with DNBSEQ-T1+ sequencing, which delivers Q40-level accuracy, throughput of 500 million–2 billion reads per flow cell, a 24-hour PE150 run time, and capacity up to 60 tumor-normal tissue pairs or 16 tumor-normal liquid biopsy pairs per flow cell.
Joint evaluation showed high concordance in variant calls and allele frequencies, plus lower background noise and reduced turnaround time versus equivalent systems. The offering is positioned for clinical labs, cancer centers, and drug developers globally.
SOPHiA GENETICS (NASDAQ: SOPH) e Complete Genomics hanno annunciato una collaborazione il 11 novembre 2025 per co-commercializzare MSK-ACCESS® e MSK-IMPACT® potenziati con SOPHiA DDM™ sulla nuova piattaforma di sequenziamento DNBSEQ-T1+ di Complete Genomics.
Il flusso di lavoro integrato dal campione al report si propone di sostenere la ricerca in oncologia di precisione combinando test validati da MSK e analisi AI con la sequencing DNBSEQ-T1+, che offre accuratezza a livello Q40, una throughput di 500 milioni–2 miliardi di reads per flow cell, un tempo di run di 24 ore PE150 e una capacità fino a 60 coppie tumore-normalità o 16 coppie di biopsia liquida tumore-normalità per flow cell.
La valutazione congiunta ha mostrato alta concordanza nelle chiamate di varianti e nelle frequenze alleliche, oltre a minore rumore di fondo e a una riduzione dei tempi di ciclo rispetto a sistemi equivalenti. L'offerta è destinata a laboratori clinici, centri oncologici e sviluppatori di farmaci a livello globale.
SOPHiA GENETICS (NASDAQ: SOPH) y Complete Genomics anunciaron una colaboración el 11 de noviembre de 2025 para co-comercializar MSK-ACCESS® y MSK-IMPACT® potenciados con SOPHiA DDM™ en la nueva plataforma de secuenciación DNBSEQ-T1+ de Complete Genomics.
El flujo de trabajo integrado de la muestra al informe tiene como objetivo la investigación oncológica de precisión combinando ensayos validados por MSK y analítica de IA con la secuenciación DNBSEQ-T1+, que ofrece precisión a nivel Q40, un rendimiento de 500 millones a 2 mil millones de lecturas por flow cell, un tiempo de ejecución de 24 horas PE150 y capacidad de hasta 60 pares tumor-sano o 16 pares de biopsia líquida tumor-sano por flow cell.
La evaluación conjunta mostró alta concordancia en llamadas de variantes y frecuencias alélicas, además de menor ruido de fondo y una reducción del tiempo de entrega frente a sistemas equivalentes. La oferta está dirigida a laboratorios clínicos, centros oncológicos y desarrolladores de fármacos a nivel global.
SOPHiA GENETICS (나스닥: SOPH)와 Complete Genomics는 2025년 11월 11일에 MSK-ACCESS® 및 MSK-IMPACT®를 SOPHiA DDM™으로 구동하는 Complete Genomics의 새로운 DNBSEQ-T1+ 시퀀싱 플랫폼으로 공동 마케팅하기 위한 협력을 발표했습니다.
통합 샘플-리포트 워크플로우는 MSK-인증 어세이와 AI 분석을 DNBSEQ-T1+ 시퀀싱과 결합하여 정밀 종양학 연구를 목표로 하며, Q40 수준의 정확도, 플로우셀당 5억~20억 리드의 처리량, 24시간 PE150 실행 시간, 그리고 최대 플로우셀당 60개의 종양-정상 조직 쌍 또는 16개의 종양-정상 액체 생검 쌍의 용량을 제공합니다.
공동 평가에서 변이 호출 및 대립유전자 빈도에서 높은 일치성이 관찰되었고, 배경 소음 감소와 동등한 시스템 대비 처리 시간이 단축되었습니다. 이 제안은 전 세계의 임상 연구소, 암 센터 및 제약 개발자를 대상으로 합니다.
SOPHiA GENETICS (NASDAQ: SOPH) et Complete Genomics ont annoncé une collaboration le 11 novembre 2025 pour co-commercialiser MSK-ACCESS® et MSK-IMPACT® dotés de SOPHiA DDM™ sur la nouvelle plateforme de séquençage DNBSEQ-T1+ de Complete Genomics.
Le flux de travail intégré de l’échantillon au rapport vise la recherche en oncologie de précision en combinant des essais validés par MSK et des analyses IA avec le séquençage DNBSEQ-T1+, qui offre une précision au niveau Q40, un débit de 500 millions à 2 milliards de lectures par flow cell, un temps d’exécution de 24 heures PE150 et une capacité allant jusqu’à 60 paires tissu tumoral/normal ou 16 paires biopsies liquides tumoral/normal par flow cell.
L’évaluation conjointe a montré une grande concordance des appels de variantes et des fréquences alléliques, ainsi qu’un bruit de fond réduit et des délais d’exécution plus courts par rapport à des systèmes équivalents. L’offre s’adresse aux laboratoires cliniques, aux centres de cancérologie et aux développeurs de médicaments à l’échelle mondiale.
SOPHiA GENETICS (NASDAQ: SOPH) und Complete Genomics haben am 11. November 2025 eine Zusammenarbeit angekündigt, um MSK-ACCESS® und MSK-IMPACT®, unterstützt von SOPHiA DDM™, gemeinsam auf der neuen DNBSEQ-T1+ Sequenzierungsplattform von Complete Genomics zu vermarkten.
Der integrierte End-to-End-Workflow zielt auf Präzisionsonkologie-Forschung ab, indem MSK-validierte Assays und KI-Analytik mit der DNBSEQ-T1+-Sequenzierung kombiniert werden, die Q40-Niveau Genauigkeit, eine Durchsatzleistung von 500 Mio.–2 Mrd. Reads pro Flow Cell, eine 24-Stunden-PE150-Laufzeit und Kapazität bis zu 60 Tumor-Normal-Gewebe-Paare oder 16 Tumor-Normal-Liquid-Biopsy-Paare pro Flow Cell bietet.
Gemeinsame Bewertungen zeigten hohe Übereinstimmung bei Variantenaufrufen und Allelfrequenzen sowie geringeren Hintergrundrauschen und verkürzten Durchlaufzeiten gegenüber identischen Systemen. Das Angebot richtet sich weltweit an klinische Labore, Krebszentren und Wirkstoffentwickler.
SOPHiA GENETICS (المؤشر: SOPH) وComplete Genomics أعلنتا عن تعاون في 11 نوفمبر 2025 للتسويق المشترك لـ MSK-ACCESS® و MSK-IMPACT® مدعومين بـ SOPHiA DDM™ على منصة DNBSEQ-T1+ الجديدة من Complete Genomics.
يهدف سير العمل المتكامل من العينة إلى التقرير إلى بحث في علم الأورام الدقيق من خلال دمج اختبارات MSK المعتمدة وتحليلات الذكاء الاصطناعي مع تسلسل DNBSEQ-T1+، الذي يوفر دقة بمستوى Q40، وإنتاجية من 500 مليون إلى 2 مليار قراءة لكل وحدة تدفق، ووقت تشغيل 24 ساعة PE150، وسعة حتى 60 زوجاً من الأنسجة الورمية-الطبيعية أو 16 زوجاً من عينات الخزعة السائلة الورمية-الطبيعية لكل وحدة تدفق.
أظهرت التقييمات المشتركة توافقاً عالياً في استدعاءات المتغيرات وتواتر الأليل، بالإضافة إلى تقليل ضوضاء الخلفية وتقليل وقت التحويل مقارنةً بالأنظمة المماثلة. العروض موجهة إلى المختبرات السريرية ومراكز السرطان ومطوري الأدوية عالمياً.
- Q40-level accuracy reported for DNBSEQ-T1+
- Throughput 500M–2B reads per flow cell
- 24-hour paired-end 150bp run time
- Capacity up to 60 tissue tumor-normal pairs per flow cell
- Joint evaluation showed high concordance in variant calls and allele frequencies
- Reported lower background noise and reduced turnaround time
- None.
Insights
Integrated sequencing plus AI analytics expands scalable precision oncology testing for decentralized labs.
Pairing SOPHiA GENETICS applications MSK-IMPACT® and MSK-ACCESS® powered by SOPHiA DDM™ with Complete Genomics' DNBSEQ-T1+ offers a sample-to-report workflow that targets clinical labs, cancer centers, and drug developers. The technical claims include Q40-level accuracy, throughput from 500 million to 2 billion reads per flow cell, a 24-hour paired-end 150bp run time, and capacity of up to 60 tumor-normal tissue pairs or 16 liquid biopsy pairs per flow cell; these metrics support scalability and lower per-sample cost when implemented as described.
Key dependencies and risks center on real-world validation, regulatory and laboratory adoption, and operational integration. Joint evaluation reported highly concordant variant calls and lower background noise versus equivalent systems, but broader clinical lab adoption will depend on independent verification, local validation workflows, reagent and service availability, and training to preserve claimed turnaround and accuracy.
Watch for formal validation data, certification/validation by clinical laboratories, and commercial roll-out milestones at industry meetings such as AMP
The collaboration integrates SOPHiA GENETICS' advanced, AI-powered applications MSK-IMPACT® and MSK-ACCESS® powered by SOPHiA DDM™, developed in collaboration with Memorial Sloan Kettering Cancer Center (MSK), with Complete Genomics' newly launched DNBSEQ-T1+ sequencing platform. Together, Complete Genomics and SOPHiA GENETICS will provide an integrated, sample-to-report workflow for laboratories, marking a significant expansion of their partnership into the precision oncology research market.
"Pairing MSK-IMPACT® and MSK-ACCESS® powered with SOPHiA DDM™ with our DNBSEQ-T1+ platform creates a powerful and accessible solution for laboratories looking to scale high-quality cancer genomic profiling," said Rob Tarbox, vice president of product and marketing at Complete Genomics. "By combining MSK's rigorously validated assays, SOPHiA GENETICS' robust analytics, and our sequencing technology, we are enabling decentralized labs to deliver faster, more accurate, and more affordable insights to clinicians and researchers."
"This collaboration underscores SOPHiA GENETICS' commitment to broadening access to data-driven medicine," said Ross Muken, President, SOPHiA GENETICS. "Partnering with Complete Genomics to streamline use of MSK-IMPACT® and MSK-ACCESS® powered with SOPHiA DDM™ on the DNBSEQ-T1+ platform enables more laboratories around the world to adopt precision oncology through scalable, end-to-end genomic solutions."
The DNBSEQ-T1+, powered by proprietary DNBSEQ technology, delivers Q40-level accuracy, optimized throughput from 500 million to 2 billion reads per flow cell. Each flow cell is able to be run independently, with a 24-hour paired-end 150bp run time, offering laboratories a cost-effective and highly flexible sequencing solution. At maximum throughput, each T1+ flow cell can run up to 60 tumor-normal sample pairs for tissue, up to 16 tumor-normal sample pairs for liquid biopsy.
SOPHiA DDM™ is a technology-agnostic analytics platform that leverages AI to compute, standardize, and analyze healthcare data. Joint evaluation of MSK-IMPACT® and MSK-ACCESS® on the DNBSEQ-T1+ platform demonstrated highly concordant variant calls and allele frequencies compared with equivalent sequencing systems, while achieving lower background noise, reduced turnaround time, and seamless compatibility with existing SOPHiA DDM™ workflows.
This new offering provides clinical laboratories, cancer centers, and drug developers with a high-performance, cost-efficient path to implementing comprehensive genomic profiling for precision oncology research.
To learn more, visit the Complete Genomics Booth 1210 or SOPHiA GENETICS Booth 921 at AMP from November 11–15, 2025 or visit www.CompleteGenomics.com and www.SOPHiAGENETICS.com.
About Complete Genomics
Complete Genomics is a pioneering life sciences company that provides novel, complete sequencing solutions including sample/library preparation, lab automation, sequencing, and data analysis. The sequencing portfolio offers a full lineup of sequencers ranging from low, medium, and high throughput capacities, all powered by its proprietary DNBSEQ technology. More than 10,900 publications are based on DNBSEQ technology across a wide array of applications. To learn more, visit www.completegenomics.com.
* For Research Use Only. Not for use in diagnostic procedures.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COMand connect with us on LinkedIn.
S OPHiA DDM™ is for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the
View original content to download multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-and-complete-genomics-integrate-sequencing-and-ai-analytics-to-accelerate-adoption-of-precision-medicine-302610620.html
SOURCE SOPHiA GENETICS
FAQ
What did SOPH and Complete Genomics announce on November 11, 2025?
How accurate is the DNBSEQ-T1+ platform used with SOPHiA DDM for SOPH (NASDAQ: SOPH) workflows?
What is the sample capacity per DNBSEQ-T1+ flow cell for tissue and liquid biopsy?
Where and when was the SOPH and Complete Genomics collaboration announced?
What operational benefits did joint evaluation report for MSK-IMPACT®/MSK-ACCESS® on DNBSEQ-T1+?
How can investors or labs learn more about the SOPH (NASDAQ: SOPH) and Complete Genomics offering?
